Healthcare & Biotech Stock News

Drug approvals, clinical trial results, and healthcare stock analysis. Coverage of HIMS, LLY, UNH, NVO, ABBV, and pharma equities.

By Basis Report editorial deskReviewed by Basis Report methodology teamMethodology

HIMSAnalysis7h ago · Jun 17, 2026

Hims & Hers Director Bets $1.2M as GLP-1 Battle Heats Up

Director David B Wells purchased $1.17 million in HIMS stock on May 26, days after a 13% earnings-driven drop that Reuters tied to the company's branded weight-loss drug pivot. The rebound on June 17 comes amid Amazon's escalating GLP-1 push and two undisclosed capital transactions filed with the SEC in May and June.

TEMAnalysis3d ago · Jun 14, 2026

Tempus AI CEO Sells $7.7M After Material Agreement

Tempus AI CEO Eric Lefkofsky and four other executives sold a combined $10.3 million in shares during May 2026, following a Material Definitive Agreement filing whose counterparty remains unnamed. The selling coincides with three consecutive EPS beats, new FDA clearances, and trailing revenue growth of 36.1%.

MANEBriefMay 28 · May 28, 2026

Veradermics Hair-Loss Pill Posts Positive Results in 500-Man Trial

Veradermics' experimental oral hair-loss pill returned positive results in a 500-man trial, marking a key clinical milestone that could accelerate the path toward FDA submission.

ALHCAnalysisMay 24 · May 24, 2026

ALHC Insiders Sell $24M as Stock Slides After Earnings

Alignment Healthcare beat earnings estimates in consecutive quarters and turned profitable, but the stock fell 19% as the market apparently priced in more. A sweep of Form 4 filings shows $23.81 million in open-market C-suite sales over 90 days with zero insider purchases, a breadth of selling that the $25.15 analyst target and 33.3% revenue growth cannot fully neutralize.

APLSAnalysisMay 23 · May 23, 2026

Biogen Closes $5.6B Apellis Acquisition, APLS Delisted

Biogen completed its $5.6 billion acquisition of Apellis Pharmaceuticals on May 14, 2026, paying $41.00 per share in cash plus a contingent value right of up to $4.00, ending APLS's run as an independent public company. The deal closes on a company with $1.11 billion in trailing revenue growing at 60.9% year-over-year, though still reporting quarterly GAAP losses.

HIMSBriefMay 19 · May 19, 2026

Hims & Hers Stock Falls 9% After $350 Million Leveraged Acquisition

Hims & Hers upsized a debt raise to $350M to fund the Eucalyptus acquisition alongside an AI initiative, triggering a ~9% share decline as investors questioned balance sheet risk and distraction from the core U.S. telehealth business.

IBRXAnalysisMay 18 · May 18, 2026

ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears

ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its Anktiva immunotherapy looms in the same week. Against 167.6% revenue growth and negative $194 million in trailing free cash flow, the company is stacking catalysts as it burns toward commercial scale.

IBRXBriefMay 17 · May 17, 2026

ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling

ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk event for shareholders.

HIMSBriefMay 9 · May 9, 2026

Hims & Hers Health Faces a 15% Stock Swing on Its Weight-Loss Pivot

Hims & Hers Health heads into Q1 earnings with options traders pricing a ~15% move in either direction, making the print a binary test of whether the GLP-1 weight-loss pivot can hold up against FDA compounding restrictions on semaglutide.

OGNBriefMay 1 · May 1, 2026

Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price

Sun Pharma's all-cash offer for Organon at a 24% premium converts the stock from a fundamentals story into a merger arbitrage trade.

CPRXBriefApr 30 · Apr 30, 2026

Catalyst Pharmaceuticals Pops on Angelini Takeover Talk, Target Lifted to $32

Catalyst Pharmaceuticals shares jumped on reports of acquisition interest from Italy's Angelini Pharma, with one analyst lifting the price target to $32 against a $28.26 stock.

CHWYAnalysisApr 29 · Apr 29, 2026

Chewy Buys Modern Animal as Insiders Take Cash Off Top

Chewy announced an agreement to acquire vet-clinic operator Modern Animal, framed as a step toward a fully integrated pet healthcare ecosystem. The deal arrives alongside a derivative-suit settlement, a wave of executive equity grants, and a stock trading at $25.59 against a $40.81 analyst target.

OGNBriefApr 28 · Apr 28, 2026

Sun Pharma Buys Organon & Co. for $11.75 Billion in All-Cash Deal

Sun Pharma agreed to acquire Organon & Co. for approximately $11.75 billion in an all-cash deal at a 24% premium, sending OGN shares to a 52-week high.

HIMSBriefApr 26 · Apr 26, 2026

Hims & Hers Health Gets JPMorgan's Blessing at $35 — But the FDA Holds the Real Vote

JPMorgan initiated Hims & Hers Health at Overweight with a $35 price target, while Eli Lilly expanded its LillyDirect GLP-1 partnership, but FDA compounding enforcement remains the binary risk to the thesis.

OGNBriefApr 24 · Apr 24, 2026

Sun Pharma's $13 Billion Bid Sends Organon & Co. Surging 31%

Organon shares surged 31% on reports of a $13 billion takeover bid from Sun Pharma, though the deal remains unconfirmed and speculative.

MOHBriefApr 24 · Apr 24, 2026

Molina Healthcare Stock Jumps 14% as Lower Medical Costs Overshadow $93M Charge

Molina Healthcare stock surged 14% after Q1 2026 earnings beat estimates on lower-than-expected medical costs, with the market ignoring a $93M impairment charge as the company reaffirmed full-year targets.

NKTRBriefApr 21 · Apr 21, 2026

Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

Nektar Therapeutics is raising $250 million in a public stock offering timed to an 18.3% rally on positive alopecia trial data, a classic biotech move that funds the pipeline but dilutes existing shareholders.

LEGNBriefApr 21 · Apr 21, 2026

Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal

Eli Lilly struck a ~$7 billion deal tied to Legend Biotech's CARVYKTI cancer therapy, sending LEGN shares up as much as 18% for the stock's best session in three years.

KLRABriefApr 18 · Apr 18, 2026

Kailera Therapeutics Raises $625 Million in Biotech's Biggest IPO, Then Pops 63%

Kailera Therapeutics priced one of biotech's largest-ever IPOs at $625 million and saw shares surge roughly 63% on their first day, reflecting intense investor appetite for obesity therapeutics.

TVTXBriefApr 15 · Apr 15, 2026

Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease

Travere Therapeutics stock surged after FILSPARI became the first and only FDA-approved treatment for focal segmental glomerulosclerosis, a rare kidney scarring disease with no competing therapies.

OGNAnalysisApr 13 · Apr 13, 2026

Sun Pharma Wants to Buy Organon for $12 Billion — But Organon Carries 45x Its Cash Flow in Debt

Sun Pharmaceutical's reported $12 billion cash bid for Organon & Co. looks like a premium until you realize ~$9B of that is legacy Merck spinoff debt assumption, not equity value. With free cash flow of $190M against that debt load, the standalone Organon story isn't cheap — it's distressed-credit math wearing a women's health disguise.

TLXBriefApr 11 · Apr 11, 2026

Telix Pharmaceuticals Jumps After FDA Accepts Brain Cancer Drug Filing

FDA accepted Telix Pharmaceuticals' NDA filing for its brain cancer imaging agent Pixclara, setting up a binary approval catalyst for the $804mn-revenue radiopharmaceutical company.

OGNBriefApr 11 · Apr 11, 2026

Sun Pharma Reportedly Near $12 Billion Deal for Organon, Stock Jumps 25%

Sun Pharmaceutical is reportedly nearing a $12 billion cash acquisition of Organon & Co., sending shares up 25%, though the stock's muted reaction at $8.83 signals deep skepticism about deal completion.

IBRXBriefApr 10 · Apr 10, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning letter over misleading Anktiva promotional claims has triggered a 21% stock drop and class action lawsuits.

TEMAnalysisApr 10 · Apr 10, 2026

Tempus AI Grew Revenue 83% But Is Still Burning $112 Million a Year in Cash

Tempus AI's four consecutive EPS beats and 83% revenue growth have Wall Street setting a $75 target, but free cash flow remains -$112M. The narrowing GAAP loss is driven more by non-cash adjustments than genuine operating leverage, and growing reliance on episodic pharma data deals introduces revenue quality risk the consensus ignores.

ALHCBriefApr 8 · Apr 8, 2026

Alignment Healthcare Jumps 16% After Medicare Pays More Than Wall Street Expected

Alignment Healthcare surged 16% after CMS announced higher-than-expected 2026 Medicare Advantage reimbursement rates, boosting the outlook for a company almost entirely dependent on MA revenue.

IBRXAnalysisApr 3 · Apr 3, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

The FDA issued an enforcement action calling ImmunityBio's promotional claims for ANKTIVA "misleading," directly undermining the commercial adoption narrative behind the stock's $6.7 billion valuation. With 31% annual share dilution and $309 million in cash burn against just $113 million in revenue, existing shareholders face value erosion even if the drug succeeds.

KODBriefApr 2 · Apr 2, 2026

Kodiak Sciences Aces Second Phase 3 Trial for Zenkuda in Diabetic Retinopathy

Kodiak Sciences reported positive GLOW2 Phase 3 results showing Zenkuda achieved a 62.5% response rate vs 3.3% for sham in diabetic retinopathy, giving the company two pivotal wins and a clear runway to file for FDA approval.

IBRXBriefApr 2 · Apr 2, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed statistical power in its pivotal ANKTIVA bladder cancer trial but faces an offsetting FDA warning that turns the stock into a pure regulatory coin flip.

PRAXBriefApr 1 · Apr 1, 2026

Praxis Precision Medicines Wins FDA Priority Review for Relutrigine NDA

Praxis Precision Medicines received FDA acceptance and Priority Review designation for its relutrigine NDA in rare pediatric epilepsy, compressing the approval timeline to roughly 6 months and marking a major de-risking event for the clinical-stage biotech.

CNTABriefApr 1 · Apr 1, 2026

Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push

Eli Lilly announced a deal to acquire Centessa Pharmaceuticals for up to $7.8bn, paying $6.3bn upfront to secure the biotech's orexin receptor pipeline for sleep-wake disorders.

APLSBriefMar 31 · Mar 31, 2026

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6bn in cash plus potential milestone payments, sending APLS shares up more than 100% as the deal adds Syfovre and a complement biology platform to Biogen's portfolio.

GRDNBriefMar 31 · Mar 31, 2026

Jefferies Initiates GRDN at Buy With $44 Target, Stock Surges 9.1%

Jefferies initiated Guardian Pharmacy Services (GRDN) at Buy with a $44 price target Monday, sparking a 9.1% single-day rally and establishing institutional price validation for the long-term care pharmacy operator.

KODAnalysisMar 27 · Mar 27, 2026

Kodiak Sciences Needs Second Phase 3 Trial Despite "Superiority" Claims

Kodiak Sciences announced positive GLOW2 Phase 3 results for tarcocimab tedromer, but the need for a second confirmatory study suggests regulatory complexity. Multiple Phase 3 trials typically indicate FDA feedback requiring additional evidence or suboptimal initial results.

CORTBriefMar 26 · Mar 26, 2026

Corcept Therapeutics Gets FDA Approval for Ovarian Cancer Drug

FDA approved Corcept Therapeutics' Lifyorli combination therapy for platinum-resistant ovarian cancer, marking the company's expansion into oncology.

CORTAnalysisMar 25 · Mar 25, 2026

Corcept Insider Drops $3.3M Just Before FDA Win Signals Hidden Value

A Corcept insider purchased $3.3 million in shares just before the company's FDA approval for Lifyorli, suggesting management confidence in broader platform value beyond the single approved indication. The timing and magnitude indicate the market is undervaluing Corcept's glucocorticoid receptor antagonist platform potential.

AAPGAnalysisMar 24 · Mar 24, 2026

Ascentage Pharma's Protein Degrader Pivot Signals Traditional Pipeline Crisis

Ascentage Pharma received China IND clearance for BTK protein degrader APG-3288, marking a strategic shift into unproven PROTAC technology. The pivot suggests management lacks confidence in their traditional small molecule programs that likely underpin current valuations.

NNNNAnalysisMar 23 · Mar 23, 2026

Anbio Biotechnology Management Disclosure Gap Signals Coverage Blind Spot

Anbio Biotechnology operates with minimal public disclosure, creating an information asymmetry that sophisticated investors can exploit. The company's upcoming KeyBanc forum appearance may trigger the first meaningful price discovery.